Combination treatment for anxiety and depression
AssigneePfizer Inc.
InventorHarry R. Howard JR.
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a GABA-A alpha ⅔ agonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a GABA-A alpha ⅔ agonist, and an SRI antidepressant agent.
Claims30
A pharmaceutical composition for the treatment of anxiety or depression in a mammal, comprising:
- (a) a compound that exhibits activity, respectively, as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
- (b) a GABA-A alpha ⅔ agonist or pharmaceutically acceptable salt thereof;
- and (c) a pharmaceutically acceptable carrier;
- wherein the active agents “a” and “b” above are present in amounts that render the composition effective in treating, respectively, anxiety or depression with increased efficacy.
A pharmaceutical composition according to claim 21 wherein the amount of the (SRI) anxiolytic agent or antidepressant, or pharmaceutically acceptable salt thereof, in said composition is from about 2.5 mg to about 500 mg and the amount of the GABA-A alpha ⅔ agonist or pharmaceutically acceptable salt thereof is from about 1.0 mg to about 100 mg.
A method of treating anxiety or depression in a mammal, comprising administering to said mammal:
- (a) a compound that exhibits activity as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
- and (b) a GABA-A alpha ⅔ agonist or pharmaceutically acceptable salt thereof;
- wherein the active agents “a” and “b” above are present in amounts that render the combination of the two agents effective in treating, respectively, anxiety or depression with increased efficacy.
Dependencies are inferred from the claim text.